Avalo Therapeutics Board Changes
Ticker: AVTX · Form: 8-K · Filed: Jul 16, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Jul 16, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, director-resignation, officer-compensation
Related Tickers: AVTX
TL;DR
Rothberg OUT at Avalo. Board shakeup.
AI Summary
Avalo Therapeutics, Inc. announced on July 15, 2024, a change in its board of directors. Specifically, Dr. Jonathan M. Rothberg has resigned from his position as a Class II director. The company also reported on compensatory arrangements for its officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty regarding leadership and strategic direction.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan M. Rothberg (person) — Resigning Director
- July 15, 2024 (date) — Date of earliest event reported
FAQ
Who resigned from the board of directors at Avalo Therapeutics?
Dr. Jonathan M. Rothberg resigned from his position as a Class II director.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is July 15, 2024.
What is Avalo Therapeutics, Inc.'s principal executive office address?
The address is 540 Gaither Road, Suite 400, Rockville, Maryland 20850.
What is the Commission File Number for Avalo Therapeutics, Inc.?
The Commission File Number is 001-37590.
What other information is reported under Item 5.02 of this 8-K filing?
Item 5.02 also covers the election of directors and the appointment of certain officers, as well as compensatory arrangements of certain officers.
Filing Stats: 1,271 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2024-07-16 07:36:46
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
- $500,000 — ide Dr. Doyle with (i) a base salary of $500,000 and (ii) a discretionary annual bonus w
Filing Documents
- avtx-20240715.htm (8-K) — 36KB
- exhibit101_mdxcmo.htm (EX-10.1) — 84KB
- ex-991cmoappointment.htm (EX-99.1) — 18KB
- avalologo.jpg (GRAPHIC) — 8KB
- 0001628280-24-031923.txt ( ) — 297KB
- avtx-20240715.xsd (EX-101.SCH) — 2KB
- avtx-20240715_lab.xml (EX-101.LAB) — 21KB
- avtx-20240715_pre.xml (EX-101.PRE) — 12KB
- avtx-20240715_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On July 16, 2024, the Company issued a press release announcing the appointment of Dr. Doyle as Chief Medical Officer, effective July 15, 2024. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 10.1 Employment Agreement, dated June 1 , 2024, by and between Avalo Therapeutics, Inc. and Mittie Doyl e. 99.1 Press Release dated Ju ly 1 6 , 2024. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: July 16, 2024 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 3